Ocular Therapeutix, Inc. $OCUL Shares Acquired by SG Americas Securities LLC

SG Americas Securities LLC boosted its holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 431.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 55,496 shares of the biopharmaceutical company’s stock after purchasing an additional 45,061 shares during the quarter. SG Americas Securities LLC’s holdings in Ocular Therapeutix were worth $649,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of OCUL. Pale Fire Capital SE raised its holdings in shares of Ocular Therapeutix by 20.7% in the second quarter. Pale Fire Capital SE now owns 530,135 shares of the biopharmaceutical company’s stock valued at $4,920,000 after buying an additional 90,748 shares during the last quarter. Deltec Asset Management LLC grew its holdings in shares of Ocular Therapeutix by 2.9% during the second quarter. Deltec Asset Management LLC now owns 2,794,892 shares of the biopharmaceutical company’s stock worth $25,937,000 after buying an additional 78,519 shares during the last quarter. Saturn V Capital Management LP increased its position in Ocular Therapeutix by 21.8% in the 2nd quarter. Saturn V Capital Management LP now owns 728,576 shares of the biopharmaceutical company’s stock valued at $6,761,000 after acquiring an additional 130,385 shares during the period. Truist Financial Corp raised its stake in Ocular Therapeutix by 100.0% during the 2nd quarter. Truist Financial Corp now owns 100,000 shares of the biopharmaceutical company’s stock valued at $928,000 after acquiring an additional 50,000 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in Ocular Therapeutix by 17.0% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,154 shares of the biopharmaceutical company’s stock worth $57,000 after acquiring an additional 893 shares during the period. 59.21% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. Robert W. Baird boosted their target price on Ocular Therapeutix from $17.00 to $24.00 and gave the company an “outperform” rating in a report on Friday, October 3rd. Royal Bank Of Canada reissued an “outperform” rating on shares of Ocular Therapeutix in a research note on Wednesday, November 5th. Chardan Capital restated a “buy” rating and set a $21.00 price objective on shares of Ocular Therapeutix in a research report on Tuesday, December 9th. Piper Sandler raised their target price on shares of Ocular Therapeutix from $21.00 to $31.00 and gave the stock an “overweight” rating in a research note on Friday, October 3rd. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $20.00 target price on shares of Ocular Therapeutix in a report on Monday, December 8th. Eleven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $22.56.

Ocular Therapeutix Price Performance

Ocular Therapeutix stock opened at $11.12 on Friday. The company has a market cap of $2.37 billion, a P/E ratio of -7.72 and a beta of 0.93. Ocular Therapeutix, Inc. has a one year low of $5.78 and a one year high of $16.44. The business has a fifty day moving average of $12.34 and a two-hundred day moving average of $12.03. The company has a debt-to-equity ratio of 0.27, a quick ratio of 7.78 and a current ratio of 7.85.

Ocular Therapeutix (NASDAQ:OCUL) last posted its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.02. Ocular Therapeutix had a negative net margin of 447.57% and a negative return on equity of 86.33%. The business had revenue of $14.54 million for the quarter, compared to analysts’ expectations of $14.57 million. As a group, analysts predict that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current fiscal year.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.